Conte Claudia, Fotticchia Iolanda, Tirino Pasquale, Moret Francesca, Pagano Bruno, Gref Ruxandra, Ungaro Francesca, Reddi Elena, Giancola Concetta, Quaglia Fabiana
Department of Pharmacy, University of Napoli Federico II, Via Domenico Montesano 49, 80131 Napoli, Italy.
Department of Chemical Sciences, University of Napoli Federico II, Via Cintia, 80126 Napoli, Italy.
Colloids Surf B Biointerfaces. 2016 May 1;141:148-157. doi: 10.1016/j.colsurfb.2016.01.035. Epub 2016 Jan 22.
In the last decades, nano-oncologicals bearing a polyethylene glycol (PEG) coating are being emerging as biomimetic devices able to drive their drug cargo to solid tumors through passive mechanisms. To improve selectivity toward cancer cells, nanocarriers decorated with the small ligand folate have been widely investigated. Nevertheless, a great challenge remains the effective exposition of folate on nanoparticles (NPs), which is a key prerequisite to ensure the correct binding to receptor and the following endocytic uptake. On these premises, in this study we propose a novel strategy to produce core-shell folate-targeted NPs based on diblock copolymers of poly(ε-caprolactone) (PCL) and PEG through the aid of (2-hydroxypropyl)-β-cyclodextrin (HPβCD). PCL4300-PEG2000 and PCL4300-PEG2000-Fol copolymers were synthesized, characterized and employed to produce NPs without and with HPβCD by a melting/sonication procedure. Colloidal properties of targeted NPs produced with HPβCD demonstrated a highly extended conformation of PEG chains in the shell, an enhanced interaction with a specific antibody against folate and a higher uptake in cells overexpressing folate receptor. Overall, these results suggest that proper manipulation of PEG shell conformation through HPβCD can represent a novel non-covalent strategy to modify shell features.
Colloids Surf B Biointerfaces. 2016-5-1
J Colloid Interface Sci. 2015-9-15
Int J Nanomedicine. 2015-3-16
Biomacromolecules. 2010-11-18
Int J Nanomedicine. 2020-7-10
J Biomed Mater Res A. 2012-5-5
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024
Pharmaceutics. 2021-9-22